Prostate cancer is the most common major cancer among men in the US, and the second leading cause of cancer death. African American men are diagnosed 60% more often than white men and die 2.3 times more often. Still, it is among the most controversial areas of modern medicine. In the face of confusion and controversy about the ability to distinguish between indolent and aggressive disease, prostate cancer treatment is rapidly moving toward personalized care. If African American and other high-risk men are not included in these trials and the results are not reported, these men will continue to experience the largest incidence and mortality disparity among all major cancers. PHEN joins the global campaign for clinical trials registration and reporting to support its mission to eliminate the African American prostate cancer disparity.